VIP cardiovascular research extends the VIP research cluster into the vascular biology that gave the peptide its name. The vasoactive component of vasoactive intestinal peptide was recognized in early research because of the potent vasodilatory activity that VIP demonstrates in isolated vascular preparations, and the downstream cardiovascular research has built on this foundational pharmacology across several decades.
VIP Cardiovascular Research: Coronary Vasodilation Animal Model Studies
VIP · Published April 14, 2026 · Updated May 18, 2026 · 7 min read
Quick Answer
VIP cardiovascular research examines coronary vasodilation and cardiomyocyte effects in rodent models of vasoactive intestinal peptide signaling. Studies measure vascular tone, coronary blood flow, cardiac function, and VPAC receptor-mediated cardiovascular biomarkers across standardized cardiovascular research protocols. For research use only, not for human consumption.
Research Use Only. All products are strictly for research use only (RUO). Not for human consumption. Products on this site are not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA. By purchasing, you agree that you are a qualified researcher and that products will be used solely for in-vitro research purposes.
- VPAC Receptor Distribution in Cardiovascular Tissues
- Coronary Vasodilation Research
- Cardiac Contractile Research
- Systemic Cardiovascular Effects
- Endothelial Function Research
- Ischemia Reperfusion Research
- Relationship to Other VIP Research
- Research Peptide Referenced
- Related Research Reading
- Related Research Articles
- Explore Related Products
- Frequently Asked Questions
- Glossary
Frequently Asked Questions
What is VIP in research contexts?
+
VIP (vasoactive intestinal peptide) is an endogenous 28-amino-acid neuropeptide of the secretin/glucagon superfamily. It is studied in preclinical models for vasodilation, immune modulation, circadian rhythm regulation, and pulmonary smooth muscle research through VPAC1 and VPAC2 receptor signaling.
How does VIP produce coronary vasodilation?
+
VIP activates VPAC1 receptors on coronary vascular smooth muscle, raising cAMP, activating PKA, and inhibiting myosin light chain kinase. The resulting smooth muscle relaxation produces potent coronary vasodilation documented in isolated heart and in vivo cardiovascular research.
What cardiovascular endpoints are measured with VIP?
+
Endpoints include coronary blood flow (Doppler or radioactive microspheres), myocardial oxygen consumption, blood pressure responses, cardiac contractility measures, and integrated assessment in models of myocardial ischemia and heart failure with VIP intervention.
Is VIP approved for human use?
+
Glossary
Key terms used in this article.
- VPAC1
- Vasoactive intestinal peptide receptor 1, broadly distributed, mediating immune and gastrointestinal effects of VIP.
- VPAC2
- Vasoactive intestinal peptide receptor 2, enriched in the suprachiasmatic nucleus and lung, involved in circadian and pulmonary signaling.
- Suprachiasmatic Nucleus (SCN)
- The hypothalamic master circadian pacemaker, where VPAC2 signaling is essential for synchronizing rhythmic neuronal activity.
- Vasodilation
- Widening of blood vessels resulting from relaxation of vascular smooth muscle, often mediated by nitric oxide or VIP signaling.
- Neuropeptide
- A peptide produced and released by neurons that acts as a signaling molecule in the nervous system.
More from the Blog
Continue exploring research insights and updates.
Research Use Only. All products are strictly for research use only (RUO). Not for human consumption. Products on this site are not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA. By purchasing, you agree that you are a qualified researcher and that products will be used solely for in-vitro research purposes.
